News
The failure of Roche’s Ionis-partnered tominersen in Huntington’s disease may indicate that Wave Life Sciences’ allele-specific antisense oligonucleotide candidate WVE-003 is on the right track, according to analysts at Rodman & Renshaw.
FEATURED STORIES
The lineup at the Alzheimer’s Association International Conference will provide critical insight into where the industry is headed with regard to targets being explored to vanquish the elusive neurodegenerative disease.
Regulators on both sides of the Atlantic are pushing for the withdrawal of the rare disease treatment that accounted for just 1% of Amgen’s 2025 revenue. Nevertheless, Amgen continues to defend the medicine, which was acquired in the $3.7 billion buyout of ChemoCentryx.
Psychedelics are gaining momentum in depression, with one treating physician predicting that the drug class could “wipe out the SSRIs” if safety and durability hold up.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
AbbVie’s experimental subcutaneous Parkinson’s disease drug ABBV-951 hit the mark in a 12-week Phase III study in patients with an advanced form of the disease.
Paris-based Sanofi reported its third-quarter finances, with most of its categories showing strong growth. However, not everything was rosy
Alnylam Chief Executive Officer Dr. John Maraganore, who has guided the company’s RNAi therapies from concept to commercialization, is handing over the reins of the company at the end of the year.
Differing skillsets mean that extroverts and introverts will usually approach the same job differently. Here is how each of them do it.
If you’ve been getting the itch to job search but you aren’t sure if you should, here are some reasons to possibly leave a job that might help you decide if you should stay or if you should go.
Emergent BioSolutions, the manufacturer responsible for the doses in question, is reportedly just waiting for the U.S. FDA’s signal to start shipping the vaccines.
Researchers believe the drug PUL-042 may work against COVID-19 and other respiratory infections, including all existing and future variants of SARS-CoV-2.
Novartis is the subject of a DOJ inquiry over the company’s marketing and pricing of Entresto over the past five years, receiving a Civil Investigative Demand from the government.
The letter was related to a 2021 FDA inspection connected to Sesen’s Biologics License Application for Vicineum. Read more about this sesen bio news here.